- Report
- March 2025
- 311 Pages
Global
From €4427EUR$4,950USD£3,840GBP
- Report
- March 2025
- 150 Pages
Global
From €2683EUR$3,000USD£2,327GBP
- Report
- October 2025
- 197 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- October 2025
- 190 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- October 2025
- 180 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- October 2025
- 285 Pages
Global
From €5232EUR$5,850USD£4,538GBP
- Report
- October 2025
- 462 Pages
Global
From €5232EUR$5,850USD£4,538GBP
- Report
- October 2025
- 381 Pages
Global
From €5232EUR$5,850USD£4,538GBP
- Report
- September 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- September 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- April 2025
- 200 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- February 2025
- 185 Pages
Global
From €4024EUR$4,500USD£3,491GBP
- Report
- October 2025
- 189 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 184 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 190 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 191 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 195 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 197 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 189 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 182 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP

Therapeutic Antibody Engineering is a field of biotechnology that focuses on the development of antibodies for therapeutic use. These antibodies are designed to target specific molecules or cells in the body, and can be used to treat a variety of diseases. The process of engineering therapeutic antibodies involves the use of recombinant DNA technology to create antibodies with desired properties. This technology is used to modify existing antibodies or to create new ones from scratch.
The therapeutic antibody engineering market is driven by the increasing demand for treatments for diseases such as cancer, autoimmune diseases, and infectious diseases. The market is also driven by advances in technology, which have enabled the development of more effective and efficient therapeutic antibodies.
Some companies in the therapeutic antibody engineering market include AbbVie, Amgen, AstraZeneca, Biogen, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Regeneron. Show Less Read more